Younossi ZM - Search Results

1

Paik JM, Henry L, Younossi ZM. Paik JM, et al. Among authors: younossi zm. Hepatology. 2022 Jun;75(6):1663-1664. doi: 10.1002/hep.32362. Epub 2022 Mar 8. Hepatology. 2022. PMID: 35076970 No abstract available.

2

Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States.

Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Stepanova M, et al. Among authors: younossi zm. Hepatology. 2011 Mar;53(3):737-45. doi: 10.1002/hep.24131. Epub 2011 Feb 11. Hepatology. 2011. PMID: 21319199

3

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.

Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Goodman Z. Younossi ZM, et al. Hepatology. 2011 Jun;53(6):1874-82. doi: 10.1002/hep.24268. Epub 2011 May 14. Hepatology. 2011. PMID: 21360720

4

Potential mechanisms underlying the associations between liver enzymes and risk for type 2 diabetes.

Venkatesan C, Younossi ZM. Venkatesan C, et al. Among authors: younossi zm. Hepatology. 2012 Mar;55(3):968-70. doi: 10.1002/hep.24769. Hepatology. 2012. PMID: 22362600 No abstract available.

5

Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.

Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Younossi ZM, et al. J Hepatol. 2014 Mar;60(3):530-7. doi: 10.1016/j.jhep.2013.11.009. Epub 2013 Nov 19. J Hepatol. 2014. PMID: 24269472

6

A new comorbidity model for predicting mortality in patients with cirrhosis: does it work?

Younossi ZM, Henry L, Stepanova M. Younossi ZM, et al. Gastroenterology. 2014 Jan;146(1):19-24. doi: 10.1053/j.gastro.2013.11.026. Epub 2013 Nov 25. Gastroenterology. 2014. PMID: 24287302 No abstract available.

7

Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Gerber L, Nader F, Hunt S. Younossi ZM, et al. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-59.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec 6. Clin Gastroenterol Hepatol. 2014. PMID: 24316172

8

Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).

Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Nader F, Hunt S. Younossi ZM, et al. J Hepatol. 2014 Apr;60(4):741-7. doi: 10.1016/j.jhep.2013.12.006. Epub 2013 Dec 11. J Hepatol. 2014. PMID: 24333184 Clinical Trial.

9

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.

Younossi Z, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, Coate B, DeMasi R, Picchio G, Witek J. Younossi Z, et al. Hepatology. 2013 Dec;58(6):1897-906. doi: 10.1002/hep.26437. Epub 2013 Oct 17. Hepatology. 2013. PMID: 24382638 Clinical Trial.

10

Monitoring and treatment of inactive chronic hepatitis B: is it cost-effective?

Younossi Z, Henry L. Younossi Z, et al. Hepatology. 2014 Jul;60(1):19-21. doi: 10.1002/hep.27062. Epub 2014 May 27. Hepatology. 2014. PMID: 24504789 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

632 results

Search Page